Glp1

Novo Nordisk's Wegovy gets CDSCO nod for treatment of fatty liver in India

Novo Nordisk India on Friday said it has received approval from the Central Drugs Standard Control Organisation for indication of its Wegovy injection for the treatment of fatty liver disease in India. The Central Drugs Standard Control Organisation (CDSCO) has approved a new indication for Wegovy (semaglutide injection 2.4 mg), Novo Nordisk India said in a statement. It makes Wegovy the first and only GLP-1 RA to be approved both globally and in India for the treatment of noncirrhotic Metabolic Dysfunction Associated Steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis along with a reduced calorie diet and increased physical activity, it added. MASH is a liver disease that develops due to excess fat buildup in the liver, causing chronic inflammation and liver damage. Novo Nordisk India MD Vikrant Shrotriya said the burden of MASH continues to rise in India, but treatment options are still severely limited. People with MASH face a higher risk of serious liver .

Explained: Why Nestle is tweaking flavours for people taking GLP-1 drugs

Nestle's chefs are working with people taking GLP-1 drugs to develop new flavour combinations, including potentially using more spices and pepper to compensate for dulled taste perception

Nestle to remove artificial food colourings from all products by end-2026

The world's largest food company said the move extends its clean-label strategy globally as consumers increasingly seek simpler and healthier food ingredients

GLP-1 rush exposes capacity crunch at India's drug manufacturing firms

Demand for GLP-1 drugs such as semaglutide is exposing capacity gaps across peptide APIs, sterile fill-finish facilities, injector devices and glass cartridges

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

Ozempic-style drugs tied to slower cancer spread in major new study

New findings to be presented at ASCO 2026 suggest GLP-1 medicines may help reduce cancer progression, although experts say more trials are still needed

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

CDSCO has directed states and UTs to curb surrogate advertising of GLP-1 obesity drugs amid rising sales and aggressive awareness campaigns

Generic GLP-1 sales increase, but innovators retain market share

Over 25 versions of weight-loss drugs currently available in the market

Biocon eyes in-licensing opportunities to expand biosimilars portfolio

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

DRL-Nestle JV launches Celevida product line for GLP-1 therapy patients

Dr Reddy's-Nestle Health Science JV launched Celevida GLP+ to support nutrition and muscle health among patients on GLP-1 and GIP therapies

Canada approves DRL's Ozempic generic after months of regulatory logjam

DRL is the first company to receive market authorisation for a generic semaglutide injection in Canada. It is the first generic semaglutide to be approved in a G7 country

How Chinese oral GLP-1 drugs may reshape India's obesity drug market

With cheaper GLP-1 pills entering India, access could improve significantly, but experts warn that affordability must be balanced with strong regulation and patient safety

Ashish Kacholia portfolio stock Shaily Engineering soars 31% in 3 days

The average trading volumes at the Shaily Engineering counter more than doubled with a combined 1.5 million shares changing hands on the NSE and BSE in Friday's intra-day trade.

Onesource Specialty Pharma up 5% in weak market; rallies 21% in one week

The company will continue to derive strength from the existence of experienced promoters and positive outlook for the GLP1 segment, which is expected to yield revenue to the company from FY27 onwards.

Fake Mounjaro injection manufacturing racket busted in Gurugram; 2 arrested

Authorities have unearthed a racket involving the manufacturing and sale of "fake" Mounjaro (tirzepatide) injections and arrested two persons here in this connection, an official said on Monday. A nationwide alert has been issued to detect the counterfeit injections and an investigation is underway to unravel the entire network, including all those involved in this racket, Drug Control Officer Amandeep Chauhan said. He said a Health Department team raided a residential society in Sector 62 on Monday and arrested two people, including the key accused. The accused were importing raw drugs from China and manufacturing counterfeit injections of Mounjaro. The entire racket was being run from a flat in the society. The accused supplied these illegal injections through the B2B portal Indiamart, the officer alleged. Mounjarois a weekly injectable medication for type 2 diabetesthat significantly improves blood sugar control and aids weight loss. "We received information about a fake inject

GLP-1 sees strong return dosage in China and Japan as India lags on value

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Hetero Labs targets sales of 1.5 million semaglutide pens in global rollout

Hetero plans to launch the drug in India in ‌April, focusing on building market share overseas to begin with, Managing Director Vamsi Krishna Bandi said

From treatment to trend, slimming drug boom sparks misuse concerns

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

Semaglutide generics hit Mounjaro sales, market share after patent expiry

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Eli Lilly's Mounjaro sales dip as semaglutide generics flood Indian market

Mounjaro sales in March dropped to ₹114 crore ($12.3 million) in March from ₹135 crore a month earlier, Pharmarack data show